Latest Regulatory Risk News

VHM Limited has made significant strides in developing its Goschen Rare Earths and Mineral Sands Project, securing substantial funding and critical regulatory approvals while expanding its resource base.

Mayfield Childcare Limited’s board has issued a Target’s Statement recommending shareholders reject Embark Early Education’s unsolicited takeover offer, citing undervaluation and significant risks. The offer, which includes a scrip or cash option, is seen as opportunistically timed amid Mayfield’s operational turnaround.

Atomo Diagnostics has locked in exclusive global rights to a novel liver function test that rapidly detects liver injury, expanding its footprint in point-of-care diagnostics. The test, delivered on Atomo’s Pascal platform, targets drug-induced liver injury and chronic liver conditions with significant commercial potential.

Auris Minerals Limited has been queried by the ASX following a sharp rise in its share price and trading volume, with the company denying any undisclosed information behind the surge.

Memphasys Limited has completed a $579K shortfall placement, boosting total funds raised to over $1.12 million to support the commercial rollout of its Felix™ System following recent regulatory approvals.

Proteomics International Laboratories has achieved the prestigious CAP accreditation for its US lab and installed a new mass spectrometry platform, setting the stage for the 2026 launch of its Promarker diagnostic tests in America.

Dimerix secures FDA confirmation that proteinuria reduction is a valid primary endpoint for its Phase 3 ACTION3 trial, advancing its kidney disease drug DMX-200 closer to approval.

Neurizon Therapeutics has launched a A$24.2 million equity raise to fund the next phase of clinical trials for its lead drug NUZ-001 targeting ALS, supported by a global licensing deal and a flexible convertible note facility.

The Australian Competition and Consumer Commission has given the green light to Caterpillar’s proposed acquisition of RPMGlobal, clearing a major regulatory hurdle. The deal now awaits shareholder and Foreign Investment Review Board approvals.

Magellan Asset Management has launched the Magellan Infrastructure Fund (Currency Hedged), an actively managed ETF trading on the ASX under ticker MICH, targeting global listed infrastructure with currency hedging and ESG integration.

Somerset Minerals Limited has launched a C$2.25 million flow-through share offer targeting Canadian investors, aiming to accelerate exploration activities at its Jura project. The capital raise complements a planned institutional placement and highlights both growth ambitions and inherent risks.

4DMedical has locked in $30.2 million through an underwriting agreement ensuring full exercise of its listed options, lifting its cash reserves to $63.7 million and setting the stage for a pivotal year in commercialising its CT – VQ™ technology.